Thyroid hormone

Liothyronine (T3)

The Cytomel label gives liothyronine's biological half-life as about 2-1/2 days; the app lists 24 hours, and a consensus document cites 22 and 22.9 hours from two pharmacokinetic studies.1,2

Strong evidence (the app's grade, not a conclusion of the sources)Get the app

Level after one dose

Liothyronine (T3) after one dose: 50% at ~24 h, 25% at 48 h, 12.5% at 72 h.

Drawn from the half-life in the app's model, ~24 h. The model's figures

1

Overview

Sources in this part

  1. 1Pfizer Laboratories, 2026

Liothyronine is L-triiodothyronine (T3), sold in the United States as Cytomel tablets by Pfizer; the label calls it "a synthetic form of a thyroid hormone".1 The label lists three uses: replacement in primary, secondary and tertiary congenital or acquired hypothyroidism; an adjunct to surgery and radioiodine therapy in well-differentiated thyroid cancer (pituitary TSH suppression); and a diagnostic thyroid suppression test.1 It is not indicated for benign thyroid nodules and nontoxic diffuse goiter in iodine-sufficient patients, nor for hypothyroidism during the recovery phase of subacute thyroiditis.1 The label gives 1956 as the initial US approval year.1 The label opens with a boxed warning: thyroid hormones, including Cytomel, alone or with other agents, are not to be used for obesity or weight loss.1 It adds that in euthyroid patients "doses within the range of daily hormonal requirements are ineffective for weight reduction", and that larger doses "may produce serious or even life-threatening manifestations of toxicity", particularly with sympathomimetic amines used for their anorectic effects.1 The human studies below come from a PubMed query returning 77 records and a ClinicalTrials.gov query; they test liothyronine added to levothyroxine in adults with hypothyroidism, while the label's dosing section describes switching from levothyroxine to Cytomel by discontinuing levothyroxine.1 The app grades the evidence for liothyronine as strong; that grade is the app's, not a conclusion of the sources.

2

How it works

The label states that thyroid hormones act "through control of DNA transcription and protein synthesis": T3 and T4 enter the cell nucleus and bind thyroid receptor proteins attached to DNA.1 The label adds that the physiological actions of thyroid hormones are produced predominantly by T3, with approximately 80% derived from T4 by deiodination in peripheral tissues.1 The consensus document by Jonklaas and colleagues (Thyroid, 2021) notes that with liothyronine alone "the endogenous peripheral T4 to T3 conversion is completely bypassed".2 On the label, onset of activity occurs "within a few hours" and maximum pharmacologic response "within 2 or 3 days".1

3

Half-life and pharmacokinetics

Values from the Milligram app's model.

Half-life
~24 h
Bioavailability
95%
Typical dose
5–75 mcg/day
Route
Oral
Time to peak
~2.5 h

The second column holds the app's own figures; the third holds what the label and a consensus document report.

Table 3.1Half-life and pharmacokinetics3 rows
ParameterApp's figureReported in the sources
Half-life24 hoursLabel: "The biological half-life is about 2-1/2 days" (about 60 hours). Consensus document: half-life of LT3 of 22 hours and 22.9 hours in two pharmacokinetic studies using daily doses of 30–45 and 50 µg LT3.1,2
Bioavailability95%Label: "T3 is almost totally absorbed, 95 percent in 4 hours."1
Time to peak2.5 hoursConsensus document: time to maximum concentration (Tmax) of T3 from 1.8 to 2.4 hours, with a maximum observed concentration (Cmax) from 292 ng/dL to 320 ng/dL across two studies; the same document gives 2 to 4 hours after a dose as the timing of peak serum T3 for monitoring.2

On the label, liothyronine is "not firmly bound to serum protein", and levothyroxine's higher affinity for thyroid-binding proteins partly explains its higher serum levels and longer half-life.1 The label states that the liver is the major site of degradation for both T4 and T3, that conjugates are excreted into bile and gut with enterohepatic recirculation, and that thyroid hormones are primarily eliminated by the kidneys.1 The consensus document concludes that these studies "clearly support" administering liothyronine more than once a day to keep serum T3 reasonably stable, and that once-daily liothyronine alone "produces unacceptably high-peak serum T3 levels".2 The label itself directs once-daily oral administration of the tablets.1

Level over 6 weeks

Interval between doses

Level, as a share of the peak after one 100 mg dose

As studied: once daily1.

An illustration from a pharmacokinetic model using a half-life of 24 hours. It is not a measured level or a suggested dose.

4

Human studies

The table lists the trials of liothyronine added to levothyroxine that are described in this section, with a meta-analysis of earlier trials.

Table 4.1Human studies6 rows
Study and yearDesignPeopleDose and lengthMain result
Clyde and colleagues, JAMA 20033Randomised, double-blind, placebo-controlled; military treatment facility; record type lists "Research Support, U.S. Gov't, Non-P.H.S."346 patients aged 24 to 65 years with at least a 6-month history of levothyroxine for primary hypothyroidism3Usual levothyroxine (n = 23) against levothyroxine reduced by 50 µg/day plus liothyronine 7.5 µg twice daily (n = 23); 4 months, oral3Questionnaire scores improved in both groups (control 23%, combination 12%) with statistically similar changes (P = .54); body weight and lipids did not change; 12 of 13 neuropsychological tests did not differ and the Grooved Peg Board favoured the control group3
Appelhof and colleagues, J Clin Endocrinol Metab 20054Double-blind, randomised, three-arm; record type lists "Research Support, Non-U.S. Gov't"4141 patients aged 18 to 70 years with primary autoimmune hypothyroidism4Levothyroxine (n = 48), levothyroxine/liothyronine 10:1 (n = 46) or 5:1 (n = 47); primary outcome at 15 weeks4Study medication preferred by 29.2%, 41.3% and 52.2% (trend P = 0.024); the trend was not supported by any secondary questionnaire or neurocognitive outcome; median end-point TSH 0.64, 0.35 and 0.07 microU/ml4
Grozinsky-Glasberg and colleagues, J Clin Endocrinol Metab 20065Meta-analysis of randomised trials; PubMed, EMBASE, LILACS and CENTRAL searched in September 20055Adults with clinical hypothyroidism; 11 studies, 1216 patients randomised5Combination against thyroxine monotherapy; doses and lengths are not stated in the record5No difference in bodily pain, depression, anxiety, fatigue, quality of life, body weight, cholesterol, triglycerides, LDL or HDL; adverse events did not differ between regimens5
Kaminski and colleagues, Arch Endocrinol Metab 20166Randomised, double-blind crossover; Merck S/A, Brazil supplied capsules632 adults with primary hypothyroidism on stable levothyroxine 125 or 150 µg/day (30 females)6Levothyroxine alone against levothyroxine/liothyronine 75/15 µg/day, 8 weeks each, oral6Free T4 lower on combination; TSH and T3 unchanged; resting heart rate 74.6 against 77.4 (P = 0.046); lipids, body weight and quality of life unchanged; 15% against 3% above the T3 upper limit6
Brigante and colleagues, LEVOLIO, Eur J Endocrinol 20247Randomised, double-blind, placebo-controlled; University of Modena and Reggio Emilia group; conflict of interest "None declared"7141 totally thyroidectomised subjects (70 combination, 71 placebo)7Mean daily liothyronine 5.00 µg with levothyroxine reduced by a mean 15 µg, against levothyroxine plus evening placebo; 24 weeks7Sex hormone binding globulin, other tissue markers and quality of life did not differ at 6 months; fT3/fT4 higher on combination; combination treatment required greater dose adjustments than placebo (25% vs 54%, P < .001), due to thyroid-stimulating hormone reduction, without hyperthyroidism signs or symptoms; no preference for combination7
Phan and colleagues, Front Endocrinol 20259Feasibility, double-blind, placebo-controlled; US National Institutes of Health (NIDDK) funded913 randomised, 12 analysed (5 combination, 7 placebo), adults having total thyroidectomy9Liothyronine 5 mcg twice daily plus reduced levothyroxine against levothyroxine/placebo; 24 weeks9No significant TSH difference; weight and cholesterol changes non-significant; energy expenditure change differed between groups (p=0.03); no significant quality-of-life difference; no patient-reported adverse event, and one combination-group patient needed a dose reduction for sustained TSH suppression at month 39

Deeper analysis: Clyde and colleagues, JAMA 2003

Clyde and colleagues, of the Department of Endocrinology and Metabolism at the National Naval Medical Center, Bethesda, reported a 4-month trial of 46 patients, 23 in each arm.3 Serum thyrotropin "remained similar and within the normal range in both treatment groups from baseline to 4 months".3 Questionnaire scores improved significantly in the control group (23%) and in the combination group (12%; P = .02), and the two changes were statistically similar (P = .54).3 The authors conclude that combination therapy "demonstrated no beneficial changes in body weight, serum lipid levels, hypothyroid symptoms as measured by a HRQL questionnaire, and standard measures of cognitive performance".3 The PubMed record carries no funding statement beyond the publication type "Research Support, U.S. Gov't, Non-P.H.S.", no author conflict-of-interest statement, no limitations statement and no adverse event report.3

Deeper analysis: Appelhof and colleagues, 2005

Appelhof and colleagues, of the Academic Medical Center, University of Amsterdam (senior author Wiersinga), compared levothyroxine alone with two levothyroxine/liothyronine ratios in 141 patients.4 Inclusion required levothyroxine for 6 months or more, a stable dose for 6 weeks or more, and serum TSH between 0.11 and 4.0 microU/ml.4 Secondary outcomes included questionnaires on mood, fatigue and psychological symptoms and neurocognitive tests; "scores on questionnaires and neurocognitive tests consistently ameliorated, but the amelioration was not different among the treatment groups".4 Mean body weight change was +0.1, -0.5 and -1.7 kg across the three groups (trend P = 0.01), and decrease in weight, not decrease in TSH, correlated with satisfaction.4 Of the patients who preferred combined therapy, 44% had serum TSH less than 0.11 microU/ml.4 The authors write that changes in mood, fatigue, well-being and neurocognitive function "could not satisfactorily explain why the primary outcome was in favor of LT4/LT3 combination therapy".4 The PubMed record lists the publication type "Research Support, Non-U.S. Gov't" and gives no named funder, author conflict-of-interest statement, limitations statement or discontinuation counts.4

Deeper analysis: Kaminski and colleagues, 2016

Kaminski and colleagues, of the Hospital das Clínicas, Universidade Federal do Paraná, Curitiba, ran a crossover trial in which 32 adults on levothyroxine 125 or 150 µg/day received levothyroxine alone or 75 µg levothyroxine plus 15 µg liothyronine daily for 8 weeks each, with no washout period.6 Free T4 was 1.07 ± 0.29 against 1.65 ± 0.46 ng/dL in group 1 and 0.97 ± 0.26 against 1.63 ± 0.43 ng/dL in group 2, lower on combination in both.6 Resting heart rate was 74.6 ± 9.5 on levothyroxine and 77.4 ± 9.2 on combination (P = 0.046), within the normal range, with no arrhythmias on resting ECG.6 The paper reports that "No significant adverse effects were reported, and all subjects completed the study", and that of the 33 quality-of-life items only two differed between treatments in a post hoc analysis (brittle nails and shortness of breath).6 The authors conclude that "No clear clinical benefit of the studied formulation could be observed".6 Stated limitations include that total T3 may be "falsely low due to the short half-life of liothyronine" because blood was drawn 24 hours after dosing, that patient preference was not assessed, and that the quality-of-life questionnaire "did not undergo validation in Portuguese".6 Funding: Merck S/A, Brazil provided Novothyral and Euthyrox capsules and, per the disclosure, "had no role in study design, data analysis and interpretation of data, writing of the manuscript, or decision to submit the manuscript for publication".6

Deeper analysis: LEVOLIO (Brigante and colleagues, 2024)

Brigante and colleagues, of the University of Modena and Reggio Emilia, randomised 141 totally thyroidectomised adults to levothyroxine plus liothyronine (morning levothyroxine and liothyronine, evening liothyronine) or to levothyroxine plus evening placebo.7 The primary aim was the effect on peripheral tissues as reflected by sex hormone binding globulin, with serum lipids, bone markers and quality of life as other tissue markers and outcomes.7 After 6 months "neither SHBG and other tissue markers nor quality of life differed significantly between groups".7 The fT3/fT4 ratio was 0.26 ± 0.05 on levothyroxine plus placebo against 0.32 ± 0.08 on the combination, and genetic variants in DIO2 and MCT10 "did not influence any outcomes".7 The record states that dose adjustments were needed because of TSH reduction "without hyperthyroidism signs or symptoms"; its conclusion is that the combination did not "significantly change peripheral tissue response or quality of life, despite an increase in the fT3/fT4 ratio".7 The conflict-of-interest statement reads "None declared"; the PubMed record includes no funding statement, no limitations text and no adverse event or discontinuation counts.7 The registry entry names Azienda USL Modena as lead sponsor and describes the aim as evaluating "the peripheral tissue response to the combined administration of levothyroxine (LT4) and liothyronine (LT3)" in thyroidectomised patients.8 Four of the authors (Trenti, Tagliavini, De Santis and Roli) give Azienda USL Modena, the registry's lead sponsor, as their affiliation, and the registry names Manuela Simoni, also an author, as investigator.7,8

Deeper analysis: Phan and colleagues, 2025

Phan and colleagues, with Celi senior author at UConn Health and Virginia Commonwealth University, ran a feasibility trial in total thyroidectomy, aiming for 30 participants; 13 were randomised and 12 analysed (5 combination, 7 placebo).9 Free T4 rose in the levothyroxine/placebo group (0.91 ± 0.12 to 1.17 ± 0.26 ng/dl, p=0.005) and total T3 fell (98.7 ± 10.9 to 80.7 ± 14.6 ng/dl, p=0.003), while the combination group showed a non-significant total T3 increase (96.8 ± 15.7 to 121.4 ± 23.9 ng/dl, p=0.142).9 Body weight changed by +1.7 kg on levothyroxine/placebo and -0.6 kg on the combination, and total and LDL cholesterol rose on placebo and fell on the combination, all non-significant.9 A diastolic-function measure (Tei index) differed between groups, quality-of-life scores improved in both groups without a significant difference between them, and no patient-reported adverse event was recorded, though one combination-group patient needed a dose reduction for sustained TSH suppression at month 3, attributed to oral GLP-1 analog therapy.9 The authors state limitations: an "unanticipated limited number of participants and a significant attrition rate, causing an underpowered study", last-measure-carried-forward analysis, and that "No adjustment for multiple comparisons was made".9 They also write that the liothyronine dosing "is supraphysiologic (pharmacologic)" and that recruitment was limited to total thyroidectomy.9 Funding came from two NIDDK awards, with Celi as principal investigator; Celi has served as a consultant for IBSA Institut Biochimique and Alora pharmaceuticals, "Both companies produce thyroid medication", and the authors state that neither company nor product was involved in the study.9 The article lists the registry identifier NCT05682482 in its summary and NCT04782856 in its methods; the registry assigns NCT05682482 to a different trial led by M. Medici.9,10

5

Doses reported in studies and on labels

Table 5.1Doses reported in studies and on labels9 rows
Source and populationLiothyronine doseComparator, route and lengthnReference
Cytomel label, adults with hypothyroidismStarting dosage 25 mcg once daily, increased by 25 mcg every 1 or 2 weeks if needed; usual maintenance 25 mcg to 75 mcg once dailyOral tablets; no comparator (label dosing)Not applicableCytomel label1
Cytomel label, elderly patients or patients with underlying cardiac diseaseStart 5 mcg once daily, increased in 5 mcg incrementsOral tablets; no comparator (label dosing)Not applicableCytomel label1
Cytomel label, pediatric patients with hypothyroidismStarting dosage 5 mcg once daily, with a 5 mcg increase every 3 to 4 days until the desired response; infants a few months old may require 20 mcg once daily for maintenance, 50 mcg once daily may be required at 1 year of age, and above 3 years of age the full adult dosage may be necessaryOral tablets; no comparator (label dosing)Not applicableCytomel label1
Cytomel label, thyroid suppression test75 mcg to 100 mcg dailyOral; 7 days, with radioactive iodine uptake measured before and afterNot applicableCytomel label1
Clyde 2003, primary hypothyroidism7.5 µg twice daily, with levothyroxine reduced by 50 µg/dayUsual levothyroxine; oral; 4 months46Clyde 20033
Appelhof 2005, primary autoimmune hypothyroidismLevothyroxine/liothyronine ratio 10:1 or 5:1Continued levothyroxine; 15 weeks to the primary outcome141Appelhof 20054
Kaminski 2016, primary hypothyroidism15 µg/day with levothyroxine 75 µg/day (fixed combination)Levothyroxine alone; crossover, 8 weeks each32Kaminski 20166
LEVOLIO 2024, total thyroidectomyMean 5.00 µg/day, with mean levothyroxine reduction of 15 µg/dayLevothyroxine plus evening placebo; 24 weeks141Brigante 20247
Phan 2025, total thyroidectomy5 mcg twice daily, with levothyroxine reduced by 25 mcg at the startLevothyroxine/placebo; 24 weeks12 analysedPhan 20259

The label lists 5 mcg, 25 mcg and 50 mcg tablets.1 The label states that dosing "depends on a variety of factors", including age, body weight, cardiovascular status, concomitant conditions including pregnancy, concomitant medications and co-administered food.1

The label states that adverse reactions "are primarily those of hyperthyroidism due to therapeutic overdosage".1 It lists, among others, fatigue, increased appetite, weight loss, heat intolerance, headache, nervousness, anxiety, insomnia, tremors, palpitations, tachycardia, arrhythmias, diarrhea, hair loss, menstrual irregularities and decreased bone mineral density.1 Overtreatment "may cause an increase in heart rate, cardiac wall thickness, and cardiac contractility and may precipitate angina or arrhythmias", particularly in patients with cardiovascular disease and in the elderly; atrial fibrillation is the most common arrhythmia with overtreatment in the elderly.1 Over-replacement can increase bone resorption and decrease bone mineral density "particularly in post-menopausal women".1 The label describes liothyronine as having "a narrow therapeutic index".1 In overdosage the label reports that "Cerebral embolism, seizure, shock, coma, and death have been reported", and that symptoms "may not appear until several days after ingestion".1 The label's interaction sections state that Cytomel "increases the response to oral anticoagulant therapy", may worsen glycemic control in patients with diabetes, may reduce the effects of digitalis glycosides, and may produce "marked hypertension and tachycardia" with ketamine.1 Bile acid sequestrants and ion exchange resins are listed as drugs that decrease thyroid hormone absorption, and the label notes concurrent use may reduce efficacy.1 The label contraindicates Cytomel in patients with uncorrected adrenal insufficiency.1 In the trials above, Kaminski and colleagues reported a rise in resting heart rate and more patients above the T3 upper limit on combination therapy, and also that no significant adverse effects were reported and all subjects completed the study;6 Phan and colleagues recorded no patient-reported adverse event, and one combination-group patient needed a dose reduction for sustained TSH suppression at month 3.9

7

Bloodwork and markers

The label states that in adults with primary hypothyroidism serum TSH is monitored periodically after starting or changing the dose, and that "measurement of total T3 would be most appropriate" to check the immediate response before TSH has responded.1 For secondary or tertiary hypothyroidism the label says serum TSH "is not a reliable measure" of dose adequacy and the serum T3 level is used instead.1 The label adds that changes in thyroxine-binding globulin bear on how T4 and T3 values are read, and that coagulation tests are monitored closely with oral anticoagulants.1 The consensus document calls monitoring "challenging due to the variation in serum T3 levels with current preparations".2 It also suggests that if peak serum T3 (2 to 4 hours after a dose) is within the reference range and TSH is not suppressed, the dose range is "likely to be a safe dose range", although not all patients are satisfied in this range, while stating that for long-term liothyronine, pulse and ECG checks and bone densitometry in postmenopausal women rest on "expert opinion".2

8

Regulatory and anti-doping status

In the United States the Cytomel label carries a boxed warning against use for obesity or weight loss, and gives 1956 as the initial approval year.1 In the 2026 WADA Prohibited List text, effective 1 January 2026, none of the terms liothyronine, triiodothyronine or thyroid appears in the text retrieved.11 That is a text-search result, not a statement by WADA about thyroid hormones.11 No European Medicines Agency or Australian TGA document for liothyronine was retrieved in the searches run (DailyMed, PubMed, ClinicalTrials.gov, and the WADA list).

9

Storage and handling

Sources in this part

  1. 1Pfizer Laboratories, 2026

The label gives the storage range as "between 15°C and 30°C (59°F and 86°F)".1

The consensus document states that its authors "believe that there is equipoise for a new well-designed adequately powered clinical trial of combination therapy".2 It describes monitoring of combination therapy "until the picture is clearer with respect to long-term safety", and notes that the TEARS data "raised the possibility of increased breast cancer risk".2 The ongoing trial NCT05682482 (lead sponsor M. Medici, Erasmus Medical Center; collaborators ZonMw and ACE Pharmaceuticals BV) is listed as recruiting with an estimated completion of January 2028, so the registry entry holds no results from it.10 The individual trials above enrolled 12 to 141 people and differ in population, ratio and length, and Phan and colleagues call their own trial underpowered.9 The label states that animal studies "have not been performed" to evaluate carcinogenic potential, mutagenic potential or effects on fertility of liothyronine sodium.1

What is the half-life of liothyronine?

The Cytomel label gives the biological half-life as about 2-1/2 days, and the app lists 24 hours.1 A consensus document cites half-lives of 22 hours and 22.9 hours in two pharmacokinetic studies.2

How well is liothyronine absorbed?

The Cytomel label states that T3 is almost totally absorbed, 95 percent in 4 hours, and the app lists 95%.1

How long does liothyronine take to peak?

A consensus document reports a time to maximum T3 concentration of 1.8 to 2.4 hours in two studies, and the app lists about 2.5 hours.2 The label gives onset within a few hours and maximum pharmacologic response within 2 or 3 days.1

Is liothyronine banned by WADA?

The 2026 WADA Prohibited List text retrieved contains no entry naming liothyronine, triiodothyronine or thyroid hormones.11 That is a text-search result, not a ruling by WADA.11

What does the boxed warning on liothyronine say?

The Cytomel boxed warning states that thyroid hormones are not for the treatment of obesity or for weight loss.1 It adds that larger doses may produce serious or even life-threatening toxicity, particularly with sympathomimetic amines used for their anorectic effects.1

What is liothyronine approved for in the US?

The Cytomel label lists replacement in hypothyroidism, TSH suppression as an adjunct in well-differentiated thyroid cancer, and a diagnostic thyroid suppression test.1

Does adding liothyronine to levothyroxine improve symptoms in trials?

A meta-analysis of 11 randomised trials (1216 patients) found no difference between combination and levothyroxine alone for pain, depression, anxiety, fatigue, quality of life, weight or lipids.5 Appelhof and colleagues reported a preference for the combination (29.2%, 41.3% and 52.2% across arms) that secondary outcomes did not explain.4

What side effects does the liothyronine label list?

The label states that adverse reactions are primarily those of hyperthyroidism due to therapeutic overdosage, including palpitations, tachycardia, arrhythmias, tremors, insomnia and decreased bone mineral density.1

Does liothyronine interact with warfarin?

The Cytomel label states that it increases the response to oral anticoagulant therapy.1

13

References

  1. Pfizer Laboratories. Cytomel (liothyronine sodium) tablets, for oral use. US prescribing information, DailyMed record version 15, 21 May 2026. DailyMed label
  2. Jonklaas J, Bianco AC, Cappola AR, et al. Evidence-Based Use of Levothyroxine/Liothyronine Combinations in Treating Hypothyroidism: A Consensus Document. Thyroid 2021. PMC full text
  3. Clyde PW, Harari AE, Getka EJ, Shakir KM. Combined levothyroxine plus liothyronine compared with levothyroxine alone in primary hypothyroidism: a randomized controlled trial. JAMA 2003. PMID 14665656
  4. Appelhof BC, Fliers E, Wekking EM, et al. Combined therapy with levothyroxine and liothyronine in two ratios, compared with levothyroxine monotherapy in primary hypothyroidism: a double-blind, randomized, controlled clinical trial. J Clin Endocrinol Metab 2005. PMID 15705921
  5. Grozinsky-Glasberg S, Fraser A, Nahshoni E, Weizman A, Leibovici L. Thyroxine-triiodothyronine combination therapy versus thyroxine monotherapy for clinical hypothyroidism: meta-analysis of randomized controlled trials. J Clin Endocrinol Metab 2006. PMID 16670166
  6. Kaminski J, Miasaki FY, Paz-Filho G, Graf H, Carvalho GA. Treatment of hypothyroidism with levothyroxine plus liothyronine: a randomized, double-blind, crossover study. Arch Endocrinol Metab 2016. PMC full text
  7. Brigante G, Santi D, Boselli G, et al. Randomized double-blind placebo-controlled trial on levothyroxine and liothyronine combination therapy in totally thyroidectomized subjects: the LEVOLIO study. Eur J Endocrinol 2024. PMID 38124252
  8. ClinicalTrials.gov. NCT03053115. Combined Replacement Therapy With Levothyroxine and Liothyronine in Thyroidectomized Patients. Sponsor: Azienda USL Modena. NCT03053115
  9. Phan GQ, Yavuz S, Stamatouli AM, et al. A feasibility double-blind trial of levothyroxine vs. levothyroxine-liothyronine in postsurgical hypothyroidism. Front Endocrinol 2025. PMC full text
  10. ClinicalTrials.gov. NCT05682482. LT4/LT3 Combination Therapy Versus LT4 Monotherapy in Patients with Autoimmune Hypothyroidism. Lead sponsor: M. Medici. NCT05682482
  11. World Anti-Doping Agency. World Anti-Doping Code International Standard: Prohibited List 2026. WADA list